CL2012000533A1 - Compuesto derivado de tiazol o una de sus sales, para el tratamiento y/o profilaxis de un trastorno de ansiedad seleccionado de trastorno de panico, agorafobia, trastorno obsesivo compulsivo, fobia social, trastorno de estres post-traumatico, fobia particular, entre otros. - Google Patents

Compuesto derivado de tiazol o una de sus sales, para el tratamiento y/o profilaxis de un trastorno de ansiedad seleccionado de trastorno de panico, agorafobia, trastorno obsesivo compulsivo, fobia social, trastorno de estres post-traumatico, fobia particular, entre otros.

Info

Publication number
CL2012000533A1
CL2012000533A1 CL2012000533A CL2012000533A CL2012000533A1 CL 2012000533 A1 CL2012000533 A1 CL 2012000533A1 CL 2012000533 A CL2012000533 A CL 2012000533A CL 2012000533 A CL2012000533 A CL 2012000533A CL 2012000533 A1 CL2012000533 A1 CL 2012000533A1
Authority
CL
Chile
Prior art keywords
disorder
phobia
agoraphobia
thiazole
prophylaxis
Prior art date
Application number
CL2012000533A
Other languages
English (en)
Inventor
Junya Kanda Tomoyuki Kase
Original Assignee
Kyowa Hakko Kirin Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43649340&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2012000533(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Kyowa Hakko Kirin Co Ltd filed Critical Kyowa Hakko Kirin Co Ltd
Publication of CL2012000533A1 publication Critical patent/CL2012000533A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Un agente para el trastorno y/o profilaxis de un tratamiento de ansiedad que comprende un compuesto derivado de tiazol o una de sus sales, en donde el trastorno de ansiedad es un trastorno de pánico, agorafobia, trastorno obsesivo-compulsivo, fobia social, trastorno de estrés post-traumático, fobia particular, entre otros.
CL2012000533A 2009-09-02 2012-02-29 Compuesto derivado de tiazol o una de sus sales, para el tratamiento y/o profilaxis de un trastorno de ansiedad seleccionado de trastorno de panico, agorafobia, trastorno obsesivo compulsivo, fobia social, trastorno de estres post-traumatico, fobia particular, entre otros. CL2012000533A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2009202894 2009-09-02

Publications (1)

Publication Number Publication Date
CL2012000533A1 true CL2012000533A1 (es) 2012-09-14

Family

ID=43649340

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2012000533A CL2012000533A1 (es) 2009-09-02 2012-02-29 Compuesto derivado de tiazol o una de sus sales, para el tratamiento y/o profilaxis de un trastorno de ansiedad seleccionado de trastorno de panico, agorafobia, trastorno obsesivo compulsivo, fobia social, trastorno de estres post-traumatico, fobia particular, entre otros.

Country Status (31)

Country Link
US (1) US20120172362A1 (es)
EP (1) EP2474544B1 (es)
JP (1) JP5663485B2 (es)
KR (2) KR20120047311A (es)
CN (1) CN102482271A (es)
AU (1) AU2010290424C1 (es)
BR (1) BR112012004850A2 (es)
CA (1) CA2772922C (es)
CL (1) CL2012000533A1 (es)
CY (1) CY1119483T1 (es)
DK (1) DK2474544T3 (es)
DO (1) DOP2012000056A (es)
EA (1) EA023728B1 (es)
ES (1) ES2643840T3 (es)
GE (1) GEP20156225B (es)
HR (1) HRP20171418T1 (es)
HU (1) HUE036543T2 (es)
IL (1) IL218320A (es)
LT (1) LT2474544T (es)
MA (1) MA33619B1 (es)
ME (1) ME02877B (es)
MX (1) MX2012002529A (es)
NZ (1) NZ598754A (es)
PL (1) PL2474544T3 (es)
PT (1) PT2474544T (es)
RS (1) RS56401B1 (es)
SI (1) SI2474544T1 (es)
TN (1) TN2012000093A1 (es)
UA (1) UA113383C2 (es)
WO (1) WO2011027806A1 (es)
ZA (1) ZA201202347B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7718808B2 (en) * 2003-12-26 2010-05-18 Kyowa Hakko Kirin Co., Ltd. Thiazole derivatives
MA41090A (fr) * 2014-12-03 2017-10-10 H Lundbeck As Antagoniste de a2a faiblement dosé pour le traitement du tdah et de la maladie de parkinson
JOP20200093A1 (ar) 2015-01-09 2017-06-16 Kyowa Kirin Co Ltd طريقة لإنتاج مشتق ثيازول
JO3544B1 (ar) * 2015-03-19 2020-07-05 Kyowa Kirin Co Ltd عامل علاجي للاختلال الوظيفي في الفص الجبهي

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5543415A (en) 1992-07-08 1996-08-06 Kyowa Hakko Kogyo Co., Ltd. Antidepressants
EP1666041A3 (en) 1997-09-05 2008-04-02 Kyowa Hakko Kogyo Co., Ltd. Xanthine derivatives for treating neurodegenerative disorders
US20040152659A1 (en) * 1999-05-12 2004-08-05 Fujisawa Pharmaceutical Co. Ltd. Method for the treatment of parkinson's disease comprising administering an A1A2a receptor dual antagonist
WO2000069464A1 (fr) * 1999-05-12 2000-11-23 Fujisawa Pharmaceutical Co., Ltd. Nouvelle utilisation
WO2003022283A1 (en) * 2001-09-13 2003-03-20 Schering Corporation Combination of an adenosine a2a receptor antagonist and an antidepressant or anxiolytic
US6620811B2 (en) 2001-11-19 2003-09-16 Hoffmann-La Roche Inc. Isonicotin- and nicotinamide derivatives of benzothiazoles
CN1787821A (zh) * 2003-06-10 2006-06-14 协和发酵工业株式会社 一种治疗焦虑症的方法
US7718808B2 (en) * 2003-12-26 2010-05-18 Kyowa Hakko Kirin Co., Ltd. Thiazole derivatives
US20100280023A1 (en) * 2005-06-23 2010-11-04 Kyowa Hakko Kogyo Co., Ltd. Thiazole derivatives
JP5121453B2 (ja) * 2005-08-02 2013-01-16 協和発酵キリン株式会社 睡眠障害の治療および／または予防剤
UA110097C2 (uk) * 2009-09-02 2015-11-25 Терапевтичний агент для лікування розладів настрою

Also Published As

Publication number Publication date
EP2474544A1 (en) 2012-07-11
EP2474544A4 (en) 2013-01-23
KR20120047311A (ko) 2012-05-11
PT2474544T (pt) 2017-10-03
JPWO2011027806A1 (ja) 2013-02-04
US20120172362A1 (en) 2012-07-05
DOP2012000056A (es) 2012-06-30
SI2474544T1 (sl) 2017-11-30
CY1119483T1 (el) 2018-03-07
AU2010290424A1 (en) 2012-04-19
ME02877B (me) 2018-04-20
MX2012002529A (es) 2012-04-11
IL218320A (en) 2016-06-30
JP5663485B2 (ja) 2015-02-04
WO2011027806A1 (ja) 2011-03-10
EA023728B1 (ru) 2016-07-29
LT2474544T (lt) 2017-10-25
CN102482271A (zh) 2012-05-30
AU2010290424B2 (en) 2015-11-05
MA33619B1 (fr) 2012-09-01
CA2772922C (en) 2017-11-21
NZ598754A (en) 2014-08-29
UA113383C2 (xx) 2017-01-25
KR20170044768A (ko) 2017-04-25
RS56401B1 (sr) 2018-01-31
BR112012004850A2 (pt) 2020-06-23
HRP20171418T1 (hr) 2017-11-03
GEP20156225B (en) 2015-01-26
HUE036543T2 (hu) 2018-07-30
TN2012000093A1 (en) 2013-09-19
AU2010290424C1 (en) 2016-02-18
DK2474544T3 (en) 2017-10-02
IL218320A0 (en) 2012-04-30
ES2643840T3 (es) 2017-11-24
EP2474544B1 (en) 2017-07-12
EA201270360A1 (ru) 2012-09-28
ZA201202347B (en) 2015-11-25
CA2772922A1 (en) 2011-10-03
PL2474544T3 (pl) 2017-12-29

Similar Documents

Publication Publication Date Title
CO6751239A2 (es) Compuesto bicíclico
ECSP10010526A (es) Compuesto heterociclico
CO7200281A2 (es) Composicion para control de enfermedades de plantas y aplicacion para la misma
CO6640320A2 (es) Composición de control de fitoenfermedades y metodo de control de fitoenfermedades
MX2021008281A (es) Estimuladores de guanilato ciclasa soluble (sgc).
ECSP14013329A (es) Compuestos de arylcarbonil-4-oxy-piperidina utilizados para el tratamiento de enfermedades neurodegenerativas
UY33476A (es) Estimuladores de sgc
BRPI1015966A2 (pt) "método para tratar uma formação subterrânea, e, meio de armazenamento legível por computador."
BRPI0920443A2 (pt) compostos de piperazina, agente, e, processo para combater vegetacao indesejavel.
BRPI0911612A2 (pt) composições e métodos para o tratamento da esclerose múltipla.
UY34326A (es) ?Composiciones y métodos para controlar malezas comprendiendo un polinucleótido y agente de transferencia, y que modulan acetolactato sintasa?
BRPI0906545A2 (pt) "aparelhos, sistemas e métodos de extensão da vida útil de meio de tratamento de alimento por inibição da degradação do mesmo"
DOP2016000253A (es) Nuevos compuestos
DE602006013945D1 (de) Substituierte cyclopentane oder cyclopentanone zur behandlung von augenhochdruck
CL2012000533A1 (es) Compuesto derivado de tiazol o una de sus sales, para el tratamiento y/o profilaxis de un trastorno de ansiedad seleccionado de trastorno de panico, agorafobia, trastorno obsesivo compulsivo, fobia social, trastorno de estres post-traumatico, fobia particular, entre otros.
CL2012001031A1 (es) Compuestos derivados de 2-oxo-1-pirrolidinil-imidazotiadiazol; composición farmacéutica que los comprende; útiles para el tratamiento de la epilepsia, transtornos neurológicos, entre otros.
AR100407A1 (es) Aplicaciones volátiles contra patógenos
BR112014015549A8 (pt) composto, método de inibição da atividade pak1, método para o tratamento, processo, composição, utilização de um composto e invenção
CL2014001157A1 (es) Metodo para tratar un ataque de gota que comprende administrar un compuesto de formula (i) y un segundo agente de reduccion de urato.
CL2014001127A1 (es) Metodos y composicion de fumigante que comprende hexafluoropropeno, 1,1,3,3,3-pentafluoropropeno o combinacion de los mismos.
CR11368A (es) Forma cristalina 1 de 2- ( (r)-2-metilpirrolidin-2-il) -1h-benzimidazol-4-carboxamida
BRPI0822905A2 (pt) Método para o tratamento de produtos, e, câmara climática.
CL2012000455A1 (es) Composiciones para tratar agua de recirculacion o de estancamiento que comprende polihexametileno biguanida (phmb) y una o mas sales de zinc; y metodo para controlar algas.
UY34168A (es) ?heterociclos microbiocidas, composición fungicida y método para controlar o prevenir una infestación de plantas?.
AR081730A1 (es) Composicion de control de fitoenfermedades y metodo para controlar fitoenfermedades